| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972725 | The Journal of Heart and Lung Transplantation | 2007 | 7 Pages |
Abstract
Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors (PSIs). Everolimus is indicated for use as an immunosuppressive drug in renal and heart transplantation. This report reflects the recommendations of the second German-Austrian Certican Consensus Conference, held in January 2006, for the clinical use of everolimus.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Markus MD, PhD, Andreas MD, PhD, Christoph MD, Manfred MD, PhD, Martin MD, PhD, Stephan MD, PhD, Hans MD, Certican Consensus Study Group Certican Consensus Study Group,